TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30504059

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 28966211

Group type: EXPERIMENTAL
Intervention: Single dose PCV13 followed by PPV23 after 16 weeks (bDMARD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single dose PCV13 followed by PPV23 after 24 weeks (bDMARD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Double dose PCV13 followed by PPV23 after 16 weeks (bDMARD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single dose PCV13 followed by PPV23 after 16 weeks (csDMARD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rituximab-treated participants (bDMARD)
Number of subjects: 100
Study: 27030901

Group type: EXPERIMENTAL
Intervention: Communication partner training (JOINT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: TBI SOLO
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist control group (CTRL)
Number of subjects: 44
Study: 24393750

Group type: EXPERIMENTAL
Intervention: Raisins
Number of subjects: 46

Group type: COMPARATOR
Intervention: Snacks
Number of subjects: 46
Study: 22119746

Group type: EXPERIMENTAL
Intervention: Olanzapine orally disintegrating tablet (ODT) - mean dosage 15.2 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Oral standard tablet (OST) - mean dosage 15.7 mg
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Olanzapine ODT
Number of subjects: 118

Group type: COMPARATOR
Intervention: Olanzapine OST
Number of subjects: 118
Study: 19351725

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 116

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 116
Study: 17584312

Group type: EXPERIMENTAL
Intervention: Prednisolone (2 mg/kg/day in three divided doses for 3 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 15020038

Group type: EXPERIMENTAL
Intervention: 1200 mg ibuprofen for 14 days
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Matching placebo for 14 days
Number of subjects: 1000
Study: 10953784

Group type: EXPERIMENTAL
Intervention: Rehabilitative coping skills module employing problem solving and cognitive behavioral therapy (experimental group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group of comparable schizophrenics
Number of subjects: 99
Study: 9117953

Group type: EXPERIMENTAL
Intervention: Source control system with supplemental oxygen and exhalent scavenged
Number of subjects: 22

Group type: COMPARATOR
Intervention: Routine care with supplemental oxygen by nasal prong
Number of subjects: 22
Study: 8458362

Group type: EXPERIMENTAL
Intervention: Quinapril once daily (o.d.)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Quinapril twice daily (b.i.d.)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3535399

Group type: COMPARATOR
Intervention: Carbenicillin 10 g every 8 h plus Gentamicin 80 mg every 8 h
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Latamoxef 2 g every 8 h
Number of subjects: 56

Group type: COMPARATOR
Intervention: Carbenicillin 10 g every 8 h plus Mecillinam 800 mg every 8 h
Number of subjects: 56
Study: 31298078

Group type: EXPERIMENTAL
Intervention: Lumbar Spine Instability questionnaire
Number of subjects: 172
Study: 30539540

Group type: EXPERIMENTAL
Intervention: Essential amino acid supplementation (Aminotrofic®) at 8g/day (two sachets of 4g/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Physical exercise rehabilitative programme and dietetic counseling
Number of subjects: 32
Study: 27879555

Group type: EXPERIMENTAL
Intervention: DTaP5-IPV
Number of subjects: 3270

Group type: COMPARATOR
Intervention: DTaP5+IPV
Number of subjects: 3270

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3270
Study: 24652866

Group type: EXPERIMENTAL
Intervention: Osteoarthritis (OA) label
Number of subjects: 0

Group type: COMPARATOR
Intervention: No OA label
Number of subjects: 0
Study: 24217362

Group type: EXPERIMENTAL
Intervention: Inhibitory rTMS over the contralesional IFG followed by SLT
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham stimulation followed by SLT
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inhibitory rTMS over the contralesional IFG for left-handed patients
Number of subjects: 31
Study: 21212710

Group type: EXPERIMENTAL
Intervention: TCI of REM + PRO
Number of subjects: 60

Group type: COMPARATOR
Intervention: FEN bolus infusion + DES inhalation
Number of subjects: 60
Study: 18643722

Group type: EXPERIMENTAL
Intervention: Training on the LAP Mentor VR simulator (6 sessions of 30 minutes each)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study: 16826829

Group type: EXPERIMENTAL
Intervention: Asking for the referent of a novel label
Number of subjects: 40

Group type: COMPARATOR
Intervention: Asking a non-specific question
Number of subjects: 40
Study: 15071277

Group type: EXPERIMENTAL
Intervention: Dual chamber pacing mode
Number of subjects: 506

Group type: COMPARATOR
Intervention: Ventricular backup pacing
Number of subjects: 506
Study: 11789241

Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM‐WM) therapy using Jiangtang Janshenling (JTJSL) capsule, alongside western medicine for blood glucose control, for three months.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Western medicine alone for three months.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM‐WM) therapy.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Western medicine alone.
Number of subjects: 100
Study: 9110906

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 8467540

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study: 3004799

Group type: EXPERIMENTAL
Intervention: Inhalation of aqueous solutions with varying chloride ion concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of ultrasonically nebulized fluid
Number of subjects: 0
Study: 31524435

Group type: EXPERIMENTAL
Intervention: Immediate punishment (answering repetitive questions)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Future punishment (meeting with a police officer in several weeks)
Number of subjects: 164
Study: 29267025

Group type: EXPERIMENTAL
Intervention: Phospholipid fatty acid (PLFA) profiles measured in plasma
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phospholipid fatty acid (PLFA) profiles measured in prostate tissue
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mean tissue PLFA concentrations
Number of subjects: 20
Study: 28994212

Group type: EXPERIMENTAL
Intervention: Adjuvant biochemotherapy (BCT)
Number of subjects: 402

Group type: COMPARATOR
Intervention: High-dose interferon alfa-2B (HDI)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Both treatments (BCT and HDI)
Number of subjects: 402
Study: 25188488

Group type: EXPERIMENTAL
Intervention: Sponge model
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Beef tongue model
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tongue model after sponge model
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 2
Study: 23695200

Group type: EXPERIMENTAL
Intervention: Short-term treatment with 40 mg of prednisone daily for 5 days
Number of subjects: 314

Group type: COMPARATOR
Intervention: Conventional treatment with 40 mg of prednisone daily for 14 days
Number of subjects: 314
Study: 20943046

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly for 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acitretin 0.4 mg/kg per day for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Atopic Dermatitis)
Number of subjects: 20
Study: 18725146

Group type: EXPERIMENTAL
Intervention: Guided experiential assignment with older adults (n = 52)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Guided experiential assignment with younger adults (n = 48)
Number of subjects: 100
Study: 16608948

Group type: EXPERIMENTAL
Intervention: superDimension/Bronchus system (SDBS)
Number of subjects: 13
Study: 14616416

Group type: EXPERIMENTAL
Intervention: Voriconazole 200 mg twice daily + Indinavir 800 mg three times daily (Study A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Voriconazole 200 mg twice daily + Indinavir 800 mg three times daily (Study B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Voriconazole 200 mg twice daily + Placebo (Study A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg three times daily + Voriconazole 200 mg (Study B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Indinavir 800 mg three times daily + Placebo (Study B)
Number of subjects: 32
Study: 11025238

Group type: EXPERIMENTAL
Intervention: IV ephedrine (10 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 8157385

Group type: EXPERIMENTAL
Intervention: Isokinetic training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ergometric training
Number of subjects: 21
Study: 3277079

Group type: COMPARATOR
Intervention: Low-dose beta-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29274617

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 5709

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 5709
Study: 28835218

Group type: EXPERIMENTAL
Intervention: Specialized palliative rehabilitation intervention integrated in standard oncology care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard oncology care alone
Number of subjects: 300
Study: 28179349

Group type: EXPERIMENTAL
Intervention: Single-dose RSB analgesia
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Repeated-dose RSB analgesia
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Continuous infusion RSB analgesia
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Overall satisfaction measured by NRS
Number of subjects: 56
Study: 23720347

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (TZ) treatment for 4-7 months
Number of subjects: 4

Group type: COMPARATOR
Intervention: Before treatment (baseline)
Number of subjects: 4
Study: 21856006

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone antibiotics (gatifloxacin 0.3%, moxifloxacin 0.5%, ofloxacin 0.3%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Azithromycin 1%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (untreated fellow eye)
Number of subjects: 24
Study: 19101268

Group type: EXPERIMENTAL
Intervention: Intracoronary shunt
Number of subjects: 56

Group type: COMPARATOR
Intervention: Occlusive snaring (Control)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both groups (shunted and nonshunted)
Number of subjects: 56
Study: 18705930

Group type: EXPERIMENTAL
Intervention: STRokE DOC telemedicine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Telephone consultations
Number of subjects: 400
Study: 15334790

Group type: EXPERIMENTAL
Intervention: Repaglinide plus acarbose (2 mg repaglinide 15 min before breakfast followed by 100 mg acarbose with breakfast)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Repaglinide alone (2 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Repaglinide plus acarbose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Repaglinide alone
Number of subjects: 40
Study: 11524040

Group type: EXPERIMENTAL
Intervention: 400 i.u. of oral alpha-tocopherol daily for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 9988942

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg/day
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem (120 mg twice a day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 94
Study: 7599713

Group type: EXPERIMENTAL
Intervention: Decision tree
Number of subjects: 0
Study: 2082209

Group type: EXPERIMENTAL
Intervention: Oxiracetam treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 36
Study: 347606

Group type: EXPERIMENTAL
Intervention: Taurolin administered intraperitoneally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30768758

Group type: EXPERIMENTAL
Intervention: AT + RT
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: RT
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: AT
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: AT, RT, AT + RT
Number of subjects: 137
Study: 28224745

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at a flow rate of 2 l/min
Number of subjects: 443

Group type: COMPARATOR
Intervention: Sham supplementation by nasal cannula
Number of subjects: 443
Study: 25211175

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24229373

Group type: EXPERIMENTAL
Intervention: Community Development Teams (CDTs)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard condition
Number of subjects: 176
Study: 22303707

Group type: EXPERIMENTAL
Intervention: Unblocking meridians and Du-channel massage combined with rehabilitation training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bobath technique (control group)
Number of subjects: 80
Study: 20084571

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Midazolam plus meperidine
Number of subjects: 74
Study: 16707516

Group type: EXPERIMENTAL
Intervention: Budesonide treatment
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: Higher FEV1 % predicted
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: Increase in number of cigarettes smoked
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: Annual FEV1 improvement
Number of subjects: 1128
Study: 15225146

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (non-structured intervention)
Number of subjects: 37
Study: 11423597

Group type: EXPERIMENTAL
Intervention: Computer generated ECG reports
Number of subjects: 10

Group type: COMPARATOR
Intervention: No computer generated ECG reports (control)
Number of subjects: 10
Study: 9403364

Group type: EXPERIMENTAL
Intervention: Apomorphine (continuous subcutaneous infusion for three weeks)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8197894

Group type: EXPERIMENTAL
Intervention: Paired flavor consumed immediately as malaise began to decline (short-delay group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Unpaired flavor consumed the morning after each session
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Paired flavor consumed when malaise had completely diminished (long-delay group)
Number of subjects: 45
Study: 3134446

Group type: EXPERIMENTAL
Intervention: Dimethicone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Senna extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of dimethicone and senna extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31291470

Group type: EXPERIMENTAL
Intervention: Renal transplant recipients (RTRs)
Number of subjects: 4261

Group type: COMPARATOR
Intervention: Non-transplanted comparison cohort (non-RTRs)
Number of subjects: 4261
Study: 30376796

Group type: EXPERIMENTAL
Intervention: Bench-top simulator (group E1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (group E5)
Number of subjects: 100
Study: 27671627

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26634701

Group type: EXPERIMENTAL
Intervention: Intervention group (28 villages); rapid testing of stored maize for aflatoxin, replacement of contaminated maize, and access to low-aflatoxin maize at local shops.
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Control group (28 villages); no intervention regarding aflatoxin exposure.
Number of subjects: 1223
Study: 22867539

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g and ketorolac 20 mg intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UVB irradiation
Number of subjects: 0
Study: 20828989

Group type: EXPERIMENTAL
Intervention: Bioabsorbable osteosynthesis (26 patients in bilateral sagittal ramus osteotomy, 17 patients in Le Fort I osteotomy, 8 patients in bimaxillary osteotomy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Titanium osteosynthesis (29 patients in bilateral sagittal ramus osteotomy, 11 patients in Le Fort I osteotomy, 10 patients in bimaxillary osteotomy)
Number of subjects: 101
Study: 18809631

Group type: EXPERIMENTAL
Intervention: 12.5 mg alogliptin
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: 25 mg alogliptin
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Alogliptin (both doses)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 329
Study: 15713945

Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib for at least 3 days followed by oral valdecoxib through day 10
Number of subjects: 1671

Group type: EXPERIMENTAL
Intervention: Intravenous placebo followed by oral valdecoxib
Number of subjects: 1671

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 1671
Study: 12660054

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg orally twice daily for 5 days
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study: 10752988

Group type: EXPERIMENTAL
Intervention: INF combined with hydroxyurea
Number of subjects: 143

Group type: COMPARATOR
Intervention: INF combined with cytarabine
Number of subjects: 143
Study: 8783785

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 36
Study: 6730944

Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 331

Group type: COMPARATOR
Intervention: Copper-T 200
Number of subjects: 331
Study: 31842809

Group type: EXPERIMENTAL
Intervention: Intervention group (schools receiving consumables, support kits, and structured tools)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (schools not receiving the intervention)
Number of subjects: 20
Study: 29558323

Group type: EXPERIMENTAL
Intervention: Chicory leaf methanolic extract capsule (1 gram, twice daily for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo capsule (1 gram wheat flour, twice daily for 8 weeks)
Number of subjects: 40
Study: 26166797

Group type: EXPERIMENTAL
Intervention: Aflibercept therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ranibizumab therapy
Number of subjects: 19
Study: 24281283

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 41
Study: 21193289

Group type: EXPERIMENTAL
Intervention: Aquarobic exercise program
Number of subjects: 0
Study: 19276994

Group type: EXPERIMENTAL
Intervention: Crossed pin fixation (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lateral only pin fixation (group B)
Number of subjects: 40
Study: 17587393

Group type: EXPERIMENTAL
Intervention: Nateglinide plus metformin
Number of subjects: 262

Group type: COMPARATOR
Intervention: Gliclazide plus metformin
Number of subjects: 262
Study: 15125551

Group type: EXPERIMENTAL
Intervention: Insuflon (subcutaneous indwelling catheter)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcutaneous injections
Number of subjects: 20
Study: 11453888

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine (DHC) 90 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9877014

Group type: EXPERIMENTAL
Intervention: Lorazepam (1.2 mg PO)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Scopolamine (0.3, 0.6 mg SC)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg PO)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Flumazenil (2 mg IV)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 8113065

Group type: EXPERIMENTAL
Intervention: CATCH family intervention (home-based curricula and Family Fun Nights focusing on healthier eating and increased physical activity)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CATCH family intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control schools (no family intervention)
Number of subjects: 28
Study: 3257300

Group type: EXPERIMENTAL
Intervention: Electrical stimulation with a duty-cycle ratio of 1:1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Electrical stimulation with a duty-cycle ratio of 1:3
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Electrical stimulation with a duty-cycle ratio of 1:5
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Electrical stimulation with a duty-cycle ratio of 1:1, 1:3, and 1:5
Number of subjects: 18
Study: 30061156

Group type: EXPERIMENTAL
Intervention: Silent Infarct Transfusion (SIT) Trial intervention
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Baseline infarct volume and reticulocyte count
Number of subjects: 286
Study: 27933574

Group type: EXPERIMENTAL
Intervention: Daily supplementation of 400 mg of magnesium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 100
Study: 24806747

Group type: EXPERIMENTAL
Intervention: Niaspan(®) (2 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22907079

Group type: EXPERIMENTAL
Intervention: Nonfat milk (500 ml daily for 2 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Whole milk (500 ml daily for 2 weeks)
Number of subjects: 14
Study: 20381820

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 774
Study: 17704866

Group type: EXPERIMENTAL
Intervention: Intermittent sequential compression (ISC) applied to lower extremities (Group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 60